Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Embecta Corp.EMBC · Entity 5950 | Pres, Pharm Svc&Prod Mgmt, CLO | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Embecta Corp.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,915.028 |
Reported balance
After 2026-08-12 transaction · row 1
1 source rowRow 1 · 2026-08-12 · Purchase · Acquired 20,000 · Balance 262,915.028 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 16,036 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 13, 2026 14:47 UTC | Embecta Corp. EMBC · Entity 5950 | PurchaseCommon Stock | 20,000 | $4.99 | $99,800.00 |
DisclosureSEC source: 0000947871-26-000787 · ownership.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · Pres, Pharm Svc&Prod Mgmt, CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,915.028 Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 02:21 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 19,605 | $12.57 | $246,434.85 |
DisclosureSEC source: 0000947871-25-001051 · ownership.xml · nonDerivative · entry 3 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,004.028 F3 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I and performance-based restricted stock units awarded to the reporting person pursuant to the Plan. F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 02:21 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 24,495 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-25-001051 · ownership.xml · nonDerivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,609.028 F2 · shares: Shares acquired upon the certification of performance conditions applicable to performance-based restricted stock units awarded to the reporting person pursuant to the Embecta 2022 Employee and Director Equity-Based Compensation Plan (the "Plan"). F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 02:21 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 79,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-25-001051 · ownership.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,114.028 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:20 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 5,285 | $12.00 | $63,420.00 |
DisclosureSEC source: 0000947871-25-000368 · ownership.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,438.598 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. F2 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 18:24 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 8,016 | $18.70 | $149,899.20 |
DisclosureSEC source: 0000947871-24-000965 · ownership.xml · nonDerivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,568.298 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. F2 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 18:24 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 50,803 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-24-000965 · ownership.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,584.298 F2 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| November 26, 2023 Filed Nov 29, 2023 01:19 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 3,715 | $17.49 | $64,975.35 |
DisclosureSEC source: 0000947871-23-001113 · ownership.xml · nonDerivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,359 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2023 Filed Nov 29, 2023 01:19 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 45,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-23-001113 · ownership.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,074 Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 21:10 UTC | Embecta Corp. EMBC · Entity 5950 | PurchaseCommon Stock | 4,700 | $21.67 | $101,849.00 |
DisclosureSEC source: 0001209191-23-045319 · doc4.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,333 Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 22:15 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 1,431 | $33.04 | $47,280.24 |
DisclosureSEC source: 0001209191-22-058966 · doc4.xml · nonDerivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,633 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 22:15 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 19,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058966 · doc4.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,064 Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 17:09 UTC | Embecta Corp. EMBC · Entity 5950 | GrantStock Appreciation Rights · Derivative | 16,281 | $0.00 Strike: $31.40 | $0.00 |
DisclosureSEC source: 0001209191-22-023424 · doc4.xml · derivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,281 Underlying: Common Stock · 16,281 shares Expires 2032-04-04 Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 17:09 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 16,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023424 · doc4.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,281 Read SEC document |
| April 04, 2022 Filed May 12, 2022 22:32 UTC Amendment | Embecta Corp. EMBC · Entity 5950 | GrantStock Appreciation Rights · Derivative | 54,450 | $0.00 Strike: $31.40 | $0.00 |
DisclosureSEC source: 0001209191-22-028635 · doc4a.xml · derivative · entry 3 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,600 Underlying: Common Stock · 54,450 shares Expires 2032-04-04 F5 · shares: This Form 4 is being amended to reflect a recalculation of the SARs that the reporting person received on April 4, 2022 in connection with Embecta's spinoff from BD. Read SEC document |
| April 04, 2022 Filed May 12, 2022 22:32 UTC Amendment | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 17,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028635 · doc4a.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,390 F1 · shares: This Form 4 is being amended to reflect a recalculation of the Time Vested Units ("TVUs") that the reporting person received on April 4, 2022 in connection with Embecta's spinoff from Becton, Dickinson and Company ("BD") on April 1, 2022. F2 · balance_after: This Form 4 now includes 14,577 TVUs that were received by the reporting person when he was employed by BD, which were later converted to Embecta TVUs in connection with Embecta's spinoff from BD on April 1, 2022. Read SEC document |
| April 01, 2022 Filed May 12, 2022 22:32 UTC Amendment | Embecta Corp. EMBC · Entity 5950 | OtherStock Appreciation Rights · Derivative | 104,150 | $0.00 Strike: $28.31 | $0.00 |
DisclosureSEC source: 0001209191-22-028635 · doc4a.xml · derivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC, Head Corp. Dev., Secy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,150 Underlying: Common Stock · 104,150 shares Expires 2031-11-26 F3 · shares: This Form 4 now includes Stock Appreciation Rights ("SARs") that were received by the reporting person when he was employed by BD, which were later converted to Embecta SARs in connection with Embecta's spinoff from BD on April 1, 2022. F4 · derivative.exercise_date: The SARs vest in four annual installments beginning November 26, 2022. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:26 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 16,036 | $80.59 | $1,292,341.24 |
DisclosureSEC source: 0001104659-21-075857 · tm2118222-12_4seq1.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · shares: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · shares: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| October 10, 2020 Filed Oct 13, 2020 16:08 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 525 | $47.36 | $24,864.00 |
DisclosureSEC source: 0000019446-20-000094 · wf-form4_160261971230149.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,036 F1 · shares: This represents shares withheld for taxes attributable to vesting of time-based RSUs that vested on 10/10/2020. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 14:27 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 9,530 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-20-000075 · wf-form4_160226805823260.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,561 F1 · shares: This represents time-based Restricted Stock Units granted on 10/7/20 that vest in three equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 08:47 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 101 | $47.25 | $4,772.25 |
DisclosureSEC source: 0000019446-20-000059 · wf-form4_159663162764425.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,031 F1 · shares: This represents shares withheld for taxes attributable to vesting of time-based RSUs that vested on 8/3/2020. Read SEC document |
| January 23, 2020 Filed Jan 23, 2020 16:27 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | PurchaseCommon Stock, par value $0.10 per share | 750 | $67.30 | $50,475.00 |
DisclosureSEC source: 0000019446-20-000008 · wf-form4_157981483142045.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,132 Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 11:19 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | Tax withholdingCommon Stock, par value $.10 per share | 145 | $68.89 | $9,989.05 |
DisclosureSEC source: 0000019446-19-000061 · edgar.xml · nonDerivative · entry 2 Mann Jeffrey Z · CIK 0001784562 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,382 F2 · shares: This represents shares withheld for taxes attributable to the vesting of RSUs on 10/10/19. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 11:19 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | GrantCommon Stock, par value $.10 per share | 3,630 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-19-000061 · edgar.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, GC and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,527 F1 · shares: This represents time-based Restricted Stock Units (RSUs) granted on 10/10/19 that vest in three equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:22 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 101 | $92.28 | $9,320.28 |
DisclosureSEC source: 0000019446-19-000049 · edgar.xml · nonDerivative · entry 1 Mann Jeffrey Z · CIK 0001784562 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 F1 · shares: This represents shares withheld for taxes attributable to the vesting of time-based RSUs that vested on 8/1/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.